Pacific Biosciences of California (PACB) Contingent consideration fair value adjustment — Quarterly & Annual

Screener

Contingent consideration fair value adjustment at other companies

InsmedINSM

-$46.96M-357%

BlackrockBLK

$180M+2,100%

ANI PharmaceuticalsANIP

-$622K—

Lifetime BrandsLCUT

$0—

Lifetime BrandsLCUT

$0—

ANI PharmaceuticalsANIP

$0—

Segments

By segment

Reportable Segment$0—

Other financials

Income statement

Revenue$39.0M-1.9%

Gross profit$12.6M-13.9%

Operating income-$44.6M+0.5%

Net income-$44.7M-6.7%

EPS (diluted)-$0.140.0%

Balance sheet

Cash & equivalents$62.6M+10.5%

Total debt$61.8M+17.1%

Total equity-$33.2M-154%

Total assets$751.9M-8.9%

Cash flow

Operating cash flow-$35.6M-21.1%

CapEx$1.6M+183%

Free cash flow-$37.1M-24.1%

Valuation

Market cap$357.46M-5.6%

Enterprise value$356.64M-4.8%

P/S2.2×-0.2×

Profitability

Gross margin36.4%+15.0pp

Operating margin-83.5%-37.4pp

Net margin-82.5%-35.5pp

FCF margin-77.5%-13.2pp

Returns & leverage

Return on equity-273.6%+314pp

Debt / equity25.1×+24.5×

Current ratio4.9×-2.0×